Payment overview · 2025
General Payments
$351.43
11 reported records · 6 companies
Healthcare provider profile · identity verified
Tamara Kramskiy, MD, DO
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1497794366
Verified facts
What the public records show
CMS Open Payments records show Tamara Kramskiy, MD, DO received $351.43 in general payments during 2025 across 11 reported records.
Axsome Therapeutics, Inc. accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Zenpep by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $177.21 | 50.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.89 | 21.0% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $30.71 | 8.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.33 | 7.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.58 | 7.0% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $17.71 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $351.43 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $177.21 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.89 | 4 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $30.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
109 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
166 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 212 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 29 |
| Linzess | Linaclotide | 166 | 27 |
| Myrbetriq | Mirabegron | 146 | 20 |
| Losartan Potassium | Losartan Potassium | 140 | 21 |
| Metformin Hcl | Metformin Hcl | 138 | 19 |
| Carvedilol | Carvedilol | 133 | 19 |
| Creon | Lipase/Protease/Amylase | 109 | 18 |
| Gabapentin | Gabapentin | 106 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 22 |
| Zenpep | Lipase/Protease/Amylase | 84 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 80 | 15 |
| Dexilant | Dexlansoprazole | 76 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 67 | suppressed |
| Furosemide | Furosemide | 60 | 14 |
| Simvastatin | Simvastatin | 57 | 14 |
| Synthroid | Levothyroxine Sodium | 56 | suppressed |
| Eliquis | Apixaban | 54 | suppressed |
| Jardiance | Empagliflozin | 54 | suppressed |
| Ozempic | Semaglutide | 54 | suppressed |
| Restasis | Cyclosporine | 53 | suppressed |
| Jublia | Efinaconazole | 52 | suppressed |
| Ibuprofen | Ibuprofen | 50 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 11 |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Lisinopril | Lisinopril | 43 | suppressed |
| Repaglinide | Repaglinide | 43 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 40 | suppressed |
| Omeprazole | Omeprazole | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Ztlido | Lidocaine | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Benicar | Olmesartan Medoxomil | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 13 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 21 | suppressed |
| Tacrolimus | Tacrolimus | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Otezla | Apremilast | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ibsrela | Tenapanor Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Canasa | Mesalamine | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Estrace | Estradiol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Vesicare | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $351.43 · 11 records | Axsome Therapeutics, Inc. | Andembry, FFRct, Ozempic, QULIPTA, Rybelsus, Symbravo, UBRELVY, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error